Samsung drug-making unit soars on market debut

AFP, SEOUL: Shares in Samsung’s drug-making unit soared almost six per cent on their market debut yesterday, after one of South Korea’s biggest ever initial public offerings that raised nearly $2 billion.
Samsung Biologics, a contract manufacturer of biotech drugs for global pharmaceutical firms, surged 5.88 per cent from its IPO price to close at 144,000 won ($125) in Seoul, putting its total value at about 9.5 trillion won. 
The rally came as investors snapped up pharmaceutical shares after Donald Trump victory in the US presidential election, during which rival Hillary Clinton had said she would move to lower drugs prices. The pharma sector rallied eight per cent in Seoul. 
Samsung Biologics was set up by the South Korean conglomerate in 2011 as part of a multi-billion-dollar drive to find new growth avenues including healthcare and green energy over the next decade. 
The highly anticipated IPO is the second largest in South Korea’s history, raising 2.25 trillion won ($1.96 billion), which the unit says will be used to expand production capacity and invest in research and development. 
The firm makes biopharmaceutical drugs for major firms including Bristol-Myers Squibb and Roche at plants near Seoul.
Bio-drugs, unlike chemically synthesised drugs, are made of organic, live substances such as plant or animal cells and are more complex to research and manufacture. 
Construction unit Samsung C&T and the flagship Samsung Electronics together hold a 75 per cent stake in Samsung Biologics after the share sale. 
The firm has been in the red for years with a net loss of 75.7 billion won in 2015 as it invested heavily in its two existing plants and a new facility slated to open in two years. 
Completion of the third plant is expected to make the company the world’s top contract drug manufacturer in terms of production capacity, said Woo Chang-Hee, analyst at IBK Investment & Securities. 
The global biopharmaceutical market is expected to grow to $488 billion by 2025, compared with $164 billion in 2012, due to the world’s ageing population, Woo said.  

Samsung drug-making unit soars on market debut

AFP, SEOUL: Shares in Samsungs drug-making unit soared almost six per cent on their market debut yesterday, after one of South Koreas biggest ever initial public offerings that raised nearly $2 billion. Samsung Biologics, a contract manufacturer of biotech drugs for global pharmaceutical firms, surged 5.88 per cent from its IPO price to close at 144,000 won ($125) in Seoul, putting its total value at about 9.5 trillion won. The rally came as investors snapped up pharmaceutical shares after Donald Trump victory in the US presidential election, during which rival Hillary Clinton had said she would move to lower drugs prices. The pharma sector rallied eight per cent in Seoul. Samsung Biologics was set up by the South Korean conglomerate in 2011 as part of a multi-billion-dollar drive to find new growth avenues including healthcare and green energy over the next decade. The highly anticipated IPO is the second largest in South Koreas history, raising 2.25 trillion won ($1.96 billion), which the unit says will be used to expand production capacity and invest in research and development. The firm makes biopharmaceutical drugs for major firms including Bristol-Myers Squibb and Roche at plants near Seoul. Bio-drugs, unlike chemically synthesised drugs, are made of organic, live substances such as plant or animal cells and are more complex to research and manufacture. Construction unit Samsung CT and the flagship Samsung Electronics together hold a 75 per cent stake in Samsung Biologics after the share sale. The firm has been in the red for years with a net loss of 75.7 billion won in 2015 as it invested heavily in its two existing plants and a new facility slated to open in two years. Completion of the third plant is expected to make the company the worlds top contract drug manufacturer in terms of production capacity, said Woo Chang-Hee, analyst at IBK Investment Securities. The global biopharmaceutical market is expected to grow to $488 billion by 2025, compared with $164 billion in 2012, due to the worlds ageing population, Woo said.